VenoStent Announces $2.3M in Seed Funding to Transform Vascular Access Surgery for Hemodialysis Patients
Share Article
Creative Ventures leads the funding round, with participation from IAG Capital Partners While we are laser-focused on our first indication, hemodialysis access, what’s additionally so exciting is that this approach avails to us a whole host of potential applications in ‘perivascular wrapping,’ said Geoff Lucks, VenoStent’s Co-Founder and COO. NASHVILLE, Tenn. (PRWEB) February 23, 2021
VenoStent, a Houston-based advanced materials company, today announced $2.3M in seed funding. The company leverages its unique polymer engineering technology to develop bioresorbable slip-on polymer wraps, called SelfWrap. The product is aimed to eliminate vascular surgery failures, at first targeting vascular access surgery required to initiate hemodialysis treatment for end-stage renal disease (ESRD) pat
Highlight
Veterans who receive all of their post-kidney transplant care within the Veterans Health Administration (VA) have a lower risk of death than those who receive care outside the VA through Medicare coverage, according to a recent study.
Washington, DC (February 18, 2021) In a study of kidney transplant recipients dually enrolled in the Veterans Health Administration (VA) and Medicare, use of the VA for all post-transplant care was linked with a lower risk of death than care provided outside the VA through Medicare or use of both the VA and non-VA care. The study will appear in an upcoming issue of
to Highlight Innovation and Opportunity in Kidney Health NEW YORK, Feb. 4, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney diseases to drive improved patient outcomes and advance value-based care, announced today that it will co-host a Capital Markets Day for Kidney Health with the American Society of Nephrology (ASN) on Thursday, February 11 from 8:00 a.m. - 12:30 p.m. EST. The virtual event will bring together a broad group of delegates representing the kidney community, including leading clinicians, representatives of U.S. government health agencies, kidney care innovators and investors focused on life sciences and medical technology, for a series of presentations and panel discussions on the challenges and innovations arising from kidney health and the market opportunity in this area.
American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day for Kidney Health einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
Washington, DC (February 4, 2021) The American Society of Nephrology (ASN) re- affirms its support for the Organ Procurement Organizations (OPOs) Conditions for Coverage final rule issued on November 20, 2020. The society calls for the Biden-Harris administration to implement this final policy as expediently as possible. By bringing objective and verifiable standards to assess the performance of OPOs, this final rule will increase the number of organs available for transplant and reduce racial inequity in the U.S. transplant system.
Communities of color bear the disproportionate burden of the organ shortage and the failures of the US transplant system. ASN commends recent steps by the Biden-Harris Administration to address equity in federal programs and policies - including health care - and the OPO final rule is a huge step to advance those efforts.